Thromboembolic and bleeding complications after elective cardioversion of atrial fibrillation: a nationwide cohort study.
Saga Itäinen-StrömbergMika LehtoOlli HalminenJukka PutaalaJari K HaukkaOssi LehtonenKonsta TeppoPirjo MustonenMiika LinnaJuha E K HartikainenKari Eino Juhani AiraksinenAapo L AroPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2024)
The rate of thromboembolic and bleeding complications related to ECV was low without significant difference between NOAC- and warfarin-treated patients. With warfarin, INR ≥2.5 at the time of cardioversion reduced the risk of thromboembolic complications.